Global Benign Prostatic Hyperplasia Treatment Market By Treatment Type, By Drug Class, By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings), By Geographic Scope and Forecast

Benign Prostatic Hyperplasia Treatment Market Size and Forecast

Global Benign Prostatic Hyperplasia Treatment Market size was valued at USD 9.24 Billion in 2024 and is projected to reach USD 15.65 Billion by 2031, growing at a CAGR of 6.81% from 2024 to 2031.

Benign Prostatic Hyperplasia (BPH) is a common condition affecting older men, characterized by non-cancerous enlargement of the prostate gland. This enlargement can cause urinary symptoms such as difficulty starting urination, weak urine stream, frequent urination, and inability to completely empty the bladder. BPH treatment involves managing these symptoms through medication, lifestyle changes, and potentially surgery.

Medications include alpha blockers, which relax bladder and prostate muscles, and 5-alpha reducase inhibitors, which shrink the prostate and prevent further growth. Some patients may receive a combination of both types of drugs for effective symptom management.

Minimally invasive procedures include Transurethral Resection of the Prostate (TURP), laser therapy, and UroLift, which use small implants to lift and hold the enlarged prostate tissue. Lifestyle adjustments include avoiding caffeine and alcohol, training the bladder to urinate at scheduled times, and regular physical activity.

Future BPH treatment may see pharmaceutical advances, technological innovations, personalized medicine, and combination therapies. Advances in medical science, the aging population, and the increasing demand for effective and minimally invasive treatments are driving the evolution of BPH treatment. As understanding of prostate health improves, future treatments are likely to be more diverse, targeted, and effective, reducing the impact of BPH on quality of life.

Global Benign Prostatic Hyperplasia Treatment Market Dynamics

The key market dynamics that are shaping the global benign prostatic hyperplasia treatment market include:

Key Market Drivers:

Aging Population: The global rise in the aging male population drives up demand for BPH treatments. As men age, the prevalence of BPH rises, resulting in higher treatment rates. For instance, in July 2024, the World Health Organization (WHO) highlighted the elderly's growing healthcare needs, emphasizing the importance of addressing age-related conditions such as BPH.

Advancements in Minimally Invasive Treatments: Technological innovations in minimally invasive procedures, such as laser therapies and UroLift systems, are driving market expansion. In June 2024, Boston Scientific expanded its Rezum(TM) Water Vapor Therapy in Europe, increasing its market share by offering a non-surgical option for BPH treatment.

Rising Healthcare Awareness and Access: Growing awareness of BPH and improved access to healthcare services in emerging markets are driving market growth. For instance, in May 2024, the Indian government launched a national awareness campaign on men's health, focusing on early diagnosis and treatment of BPH, thereby increasing treatment adherence.

Introduction of Combination Therapies: The development and approval of combination therapies that improve efficacy by targeting multiple BPH symptoms is driving market expansion. In April 2024 AbbVie received FDA approval for its new combination therapy for BPH, which combines an alpha-blocker and a 5-alpha reductase inhibitor, establishing a new standard for treatment options.

Key Challenges:

Side Effects of Medications: Medications used to treat BPH, such as alpha-blockers and 5-alpha reductase inhibitors, frequently cause dizziness, fatigue, and sexual dysfunction, which can lead to patient noncompliance and impede market growth.

High Costs of Advanced Treatments: Minimally invasive and surgical procedures for BPH are frequently expensive, limiting patient access, particularly in low-income areas. The high costs may serve as a barrier to market expansion.

Limited Awareness in Emerging Markets: Many developing countries have low awareness of BPH and its treatment options, resulting in underdiagnosis and undertreatment, slowing market penetration in these areas.

Competition from Alternative Therapies: The market faces competition from alternative therapies such as phytotherapy and lifestyle changes, which some patients prefer due to their natural approach and perceived safety, reducing demand for traditional treatments.

Key Trends:

Shift towards Minimally Invasive Procedures: Minimally invasive treatments such as laser therapy, UroLift, and Rezum(TM) Water Vapor Therapy are increasingly preferred over traditional surgical methods due to their shorter recovery times and fewer complications.

Increasing Use of Combination Therapies: The use of combination therapies that target multiple pathways in BPH management is on the rise, as these therapies improve efficacy and provide better symptom relief than monotherapy, resulting in better patient outcomes.

Focus on Personalized Medicine: Advances in diagnostics and genomics are opening the door to more personalized BPH treatments. Treatment plans are increasingly being tailored to individual patient profiles in order to improve efficacy and reduce side effects.

Expansion into Emerging Markets: Companies are increasingly focusing on growing their presence in emerging markets, where the aging population and increased healthcare access are driving demand for BPH treatments. This growth is aided by increased awareness and government initiatives promoting men's health in these areas.

Global Benign Prostatic Hyperplasia Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global benign prostatic hyperplasia treatment market:

North America:

North America dominates the global Benign Prostatic Hyperplasia (BPH) treatment market, owing to a combination of advanced healthcare infrastructure, high population awareness, and access to cutting-edge treatment options. The region's aging population has increased demand for effective treatments ranging from medications to minimally invasive procedures, resulting in a high prevalence of BPH. The strong presence of major pharmaceutical companies, as well as ongoing research and development efforts, help North America maintain its market leadership. In June 2024, Pfizer announced positive results from a clinical trial of a new alpha-blocker drug, reinforcing the region's status as a center of BPH treatment innovation.

Furthermore, government initiatives and healthcare policies in North America have helped to drive the growth of the BPH treatment market. The United States government's focus on improving men's health, combined with insurance coverage for various BPH treatments, has made advanced therapies more accessible to patients. In May 2024, the FDA approved a new minimally invasive device for BPH treatment, demonstrating the region's commitment to providing the most up-to-date and effective treatments. These factors, combined with a high rate of early diagnosis and treatment, ensure that North America continues to lead the global BPH treatment market.

Asia-Pacific:

Growing population, rising healthcare standards, and rising BPH prevalence, the Asia Pacific region is increasingly dominating the global Benign Prostatic Hyperplasia (BPH) treatment market. The region's rapid economic growth and expanding middle class are resulting in increased healthcare spending and easier access to advanced medical treatments. A significant development occurred in August 2024, when the Indian government launched a new initiative to raise prostate health awareness and expand access to BPH treatments in rural areas, resulting in further market growth.

Furthermore, the Asia Pacific market is being boosted by the growing adoption of modern healthcare technologies, as well as the entry of international pharmaceutical companies looking to capitalize on this emerging market. In July 2024, Medtronic's UroLift(R) System in China, which was announced highlighting the growing interest in minimally invasive BPH treatments in the region. These factors contribute to Asia Pacific's dominance in the BPH treatment market, indicating its potential for future growth and development.

Global Benign Prostatic Hyperplasia Treatment Market: Segmentation Analysis

The Global Benign Prostatic Hyperplasia Treatment Market is segmented on the basis of By Treatment Type, By Drug Class, By End-User and By Geography.

Global Benign Prostatic Hyperplasia Treatment Market, By Treatment Type

• Medication
• Minimally Invasive Procedures
• Surgical Procedures

Based on Treatment Type, the Global Benign Prostatic Hyperplasia Treatment Market is segmented into Medication, Minimally Invasive Procedures, and Surgical Procedures. Medication is the most popular segment due to its non-invasive nature, ease of administration, and widespread use in treating BPH symptoms. The fastest-growing segment is minimally invasive procedures, which are driven by technological advancements, shorter recovery times, and an increasing patient preference for less invasive treatment options.

Global Benign Prostatic Hyperplasia Treatment Market, By Drug Class

• Alpha Blockers

5-Alpha Reductase Inhibitors

• Combination Therapy
• Phytotherapy

Based on Drug Class, the Global Benign Prostatic Hyperplasia Treatment Market is segmented into Alpha Blockers, 5-Alpha Reductase Inhibitors, Combination Therapy, and Phytotherapy. Alpha blockers dominate the market as they are widely used as the first-line treatment for urinary symptoms, providing quick relief. Combination Therapy is the fastest-growing segment, driven by its ability to manage multiple BPH symptoms by combining the benefits of Alpha Blockers and 5-Alpha Reductase Inhibitors.

Global Benign Prostatic Hyperplasia Treatment Market, By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Homecare Settings

Based on End-User, the Global Benign Prostatic Hyperplasia Treatment Market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Homecare Settings. Hospitals are the dominant segment due to their extensive treatment options, advanced facilities, and ability to handle complex cases. Ambulatory Surgical Centers (ASCs) are the fastest-growing segment, driven by the growing demand for minimally invasive procedures, shorter recovery times, and cost-effective treatment options outside of traditional hospital settings.

Global Benign Prostatic Hyperplasia Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Benign Prostatic Hyperplasia Treatment Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America is the dominant region due to its high prevalence of BPH, advanced healthcare infrastructure, and widespread use of innovative treatments. Asia Pacific is the fastest-growing region, owing to an aging population, increased healthcare awareness, and improved access to advanced medical treatments in emerging markets.

Key Players

The "Global Benign Prostatic Hyperplasia Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, AbbVie (Allergan Plc), Astellas, Inc., Boehringer Ingelheim GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Benign Prostatic Hyperplasia Treatment Market: Recent Developments
• In February 2024, The FDA approved AbbVie's new combination therapy for BPH, which combines a 5-alpha-reductase inhibitor and an alpha blocker. This therapy is expected to improve patient adherence while also treating multiple symptoms.
• In January 2024, Medtronic expanded its portfolio by acquiring a startup that specializes in advanced BPH treatments via radiofrequency ablation. This acquisition is expected to expand Medtronic's minimally invasive treatment options in the BPH market.
• In April 2024 , GlaxoSmithKline: GSK introduced a new formulation of its alpha-blocker medication for BPH in Asia Pacific, which is intended to provide better tolerance and fewer side effects. This move is part of GSK's strategy to increase its market share in emerging markets.
• In March 2024, Olympus Corporation launches its latest laser therapy device for BPH in North America, offering a more precise and minimally invasive treatment option for enlarged prostate conditions. This product aims to shorten treatment times while improving patient outcomes.
• Analyst's Take
• The Benign Prostatic Hyperplasia Treatment Market is witnessing steady growth owing to several factors such as the aging population demographic, increasing awareness about prostate health, and advancements in medical technology. Pharmaceutical companies are developing innovative drugs with improved efficacy and safety profiles, while medical device manufacturers are introducing minimally invasive treatment options offering reduced recovery times and enhanced patient outcomes. Additionally, strategic collaborations between healthcare providers, research institutions, and industry players are fostering the development of personalized treatment approaches tailored to individual patient needs. As a result, the BPH treatment market is poised for further expansion in the coming years, presenting lucrative opportunities for stakeholders across the healthcare continuum.